UK scheme to tackle "historically low" numbers of people taking part in dementia trials launches with £20m in government funding.

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA ...